Heidelberg Pharma (HPHA.DE) Performance Snapshot – 24‑Hour View
Heidelberg Pharma shares closed up 0.91 % during the 24‑hour period ending at 05:51 AM Central Europe on Thursday, 22 May 2026. The current trading price on popular exchanges is approximately EUR 2.16 per share.
- Supply and Market Capitalisation – The stock is available in a total supply of 46.8 million shares. With the prevailing share price, the company’s market cap stands at EUR 104.3 million.
- Trading Volume – In the last 24 hours, roughly EUR 4 000 worth of shares have changed hands.
- Recent Performance – Since the end of April, Heidelberg Pharma has fallen 10.84 %.
- Technical Indicators – The 200‑day simple moving average sits at EUR 2.71. The 52‑week high and low are EUR 3.34 (recorded on 01 Sep 2026) and EUR 2.15 (on 16 Oct 2026), respectively.
Peer Comparison – 24‑Hour Movements
| Stock | 24‑h Change | Current Price (EUR) | Market Cap (EUR mn) | P/E Ratio |
|---|---|---|---|---|
| Electrovac (EVAC.DE) | +1.26 % | 7.75 | 114.6 | 10.63 |
| Pyrum Innovations (PYR.F) | 0 % | 26.9 | 107.7 | – |
| Mineralbrunnen Ueberkingen (MUT.SG) | –4.73 % | 14.1 | 107.3 | 21.16 |
| Schloss Wachenheim (SWA.DE) | 0 % | 14.7 | 118.0 | 14.56 |
| Knaus Tabbert (KTA.DE) | –1.05 % | 9.82 | 98.9 | – |
Heidelberg Pharma’s modest rally contrasts with the broader volatility observed among its peers. While Electrovac enjoys a favorable P/E of 10.63, Mineralbrunnen’s higher ratio of 21.16 may signal valuation compression for that sector.
Strategic Context
Heidelberg Pharma AG, headquartered in Germany, focuses on the development and commercialization of novel oncology and anti‑inflammatory therapeutics. The firm’s research portfolio spans pharmacology, drug metabolism, pharmacokinetics, and molecular biology, targeting both cancer and inflammatory diseases. Since its initial public offering on 13 November 2006, the company has maintained a consistent presence on the Xetra exchange, serving both patients and healthcare professionals across Germany.
Forward‑Looking Perspective
Despite a recent decline, Heidelberg Pharma’s technical profile suggests a potential support area near the 200‑day moving average. The current price of EUR 2.16 is comfortably below the 52‑week high of EUR 3.34, implying room for upside if the company capitalises on its pipeline progress or strategic partnerships. Investors monitoring the sector should also consider the company’s valuation relative to peers, noting that its P/E and market cap align with mid‑cap biotech firms operating in competitive therapeutic domains.
